MHC2-SCALE enhances identification of immunogenic neoantigens

Summary: Recent studies suggest that CD4+ T cells can exert potent anti-tumor effects and improve immunotherapy efficacy by aiding CD8+ T cells. However, characterizing the mechanism of CD4+ T cells’ anti-tumor activity has been challenging due to inaccurate major histocompatibility complex class II...

Full description

Saved in:
Bibliographic Details
Main Authors: Joshua G. Gober, Aude-Hélène Capietto, Reyhane Hoshyar, Martine Darwish, Richard Vandlen, Jonathan L. Linehan, Lélia Delamarre, Adel M. ElSohly
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:iScience
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004225004730
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850260225820459008
author Joshua G. Gober
Aude-Hélène Capietto
Reyhane Hoshyar
Martine Darwish
Richard Vandlen
Jonathan L. Linehan
Lélia Delamarre
Adel M. ElSohly
author_facet Joshua G. Gober
Aude-Hélène Capietto
Reyhane Hoshyar
Martine Darwish
Richard Vandlen
Jonathan L. Linehan
Lélia Delamarre
Adel M. ElSohly
author_sort Joshua G. Gober
collection DOAJ
description Summary: Recent studies suggest that CD4+ T cells can exert potent anti-tumor effects and improve immunotherapy efficacy by aiding CD8+ T cells. However, characterizing the mechanism of CD4+ T cells’ anti-tumor activity has been challenging due to inaccurate major histocompatibility complex class II (MHC-II) peptide prediction algorithms and the lack of high-quality reagents for immune monitoring. To address this, we developed MHC2—substitution of CLIP and analytical LCMS evaluation (MHC2-SCALE), a streamlined approach combining affinity optimized class II-associated invariant chain peptide (CLIP) exchange technology, high throughput 2D-LCMS analysis, and rapid generation of peptide-bound MHC-II monomers for subsequent multimer assembly. We validated MHC-II peptide candidates predicted by the immune epitope database (IEDB) algorithm, as well as uncovered many true and immunogenic MHC-II binders that were not predicted by IEDB. Thus, MHC2-SCALE expands the opportunities for discovering, tracking, and phenotyping antigen-specific CD4+ T cells in preclinical and clinical settings, thereby improving therapies for cancer, autoimmunity, or infectious diseases.
format Article
id doaj-art-df286200c40e4e12a49df22ade8a0a5d
institution OA Journals
issn 2589-0042
language English
publishDate 2025-04-01
publisher Elsevier
record_format Article
series iScience
spelling doaj-art-df286200c40e4e12a49df22ade8a0a5d2025-08-20T01:55:41ZengElsevieriScience2589-00422025-04-0128411221210.1016/j.isci.2025.112212MHC2-SCALE enhances identification of immunogenic neoantigensJoshua G. Gober0Aude-Hélène Capietto1Reyhane Hoshyar2Martine Darwish3Richard Vandlen4Jonathan L. Linehan5Lélia Delamarre6Adel M. ElSohly7Department of Protein Chemistry, Genentech Inc, South San Francisco, CA, USACancer Immunology Department, Genentech Inc, South San Francisco, CA, USACancer Immunology Department, Genentech Inc, South San Francisco, CA, USADepartment of Protein Chemistry, Genentech Inc, South San Francisco, CA, USADepartment of Protein Chemistry, Genentech Inc, South San Francisco, CA, USACancer Immunology Department, Genentech Inc, South San Francisco, CA, USACancer Immunology Department, Genentech Inc, South San Francisco, CA, USADepartment of Protein Chemistry, Genentech Inc, South San Francisco, CA, USA; Department of Immunology Discovery, Genentech Inc, South San Francisco, CA, USA; Corresponding authorSummary: Recent studies suggest that CD4+ T cells can exert potent anti-tumor effects and improve immunotherapy efficacy by aiding CD8+ T cells. However, characterizing the mechanism of CD4+ T cells’ anti-tumor activity has been challenging due to inaccurate major histocompatibility complex class II (MHC-II) peptide prediction algorithms and the lack of high-quality reagents for immune monitoring. To address this, we developed MHC2—substitution of CLIP and analytical LCMS evaluation (MHC2-SCALE), a streamlined approach combining affinity optimized class II-associated invariant chain peptide (CLIP) exchange technology, high throughput 2D-LCMS analysis, and rapid generation of peptide-bound MHC-II monomers for subsequent multimer assembly. We validated MHC-II peptide candidates predicted by the immune epitope database (IEDB) algorithm, as well as uncovered many true and immunogenic MHC-II binders that were not predicted by IEDB. Thus, MHC2-SCALE expands the opportunities for discovering, tracking, and phenotyping antigen-specific CD4+ T cells in preclinical and clinical settings, thereby improving therapies for cancer, autoimmunity, or infectious diseases.http://www.sciencedirect.com/science/article/pii/S2589004225004730Biological sciencesBiochemistry methodsImmunologyProteomics
spellingShingle Joshua G. Gober
Aude-Hélène Capietto
Reyhane Hoshyar
Martine Darwish
Richard Vandlen
Jonathan L. Linehan
Lélia Delamarre
Adel M. ElSohly
MHC2-SCALE enhances identification of immunogenic neoantigens
iScience
Biological sciences
Biochemistry methods
Immunology
Proteomics
title MHC2-SCALE enhances identification of immunogenic neoantigens
title_full MHC2-SCALE enhances identification of immunogenic neoantigens
title_fullStr MHC2-SCALE enhances identification of immunogenic neoantigens
title_full_unstemmed MHC2-SCALE enhances identification of immunogenic neoantigens
title_short MHC2-SCALE enhances identification of immunogenic neoantigens
title_sort mhc2 scale enhances identification of immunogenic neoantigens
topic Biological sciences
Biochemistry methods
Immunology
Proteomics
url http://www.sciencedirect.com/science/article/pii/S2589004225004730
work_keys_str_mv AT joshuaggober mhc2scaleenhancesidentificationofimmunogenicneoantigens
AT audehelenecapietto mhc2scaleenhancesidentificationofimmunogenicneoantigens
AT reyhanehoshyar mhc2scaleenhancesidentificationofimmunogenicneoantigens
AT martinedarwish mhc2scaleenhancesidentificationofimmunogenicneoantigens
AT richardvandlen mhc2scaleenhancesidentificationofimmunogenicneoantigens
AT jonathanllinehan mhc2scaleenhancesidentificationofimmunogenicneoantigens
AT leliadelamarre mhc2scaleenhancesidentificationofimmunogenicneoantigens
AT adelmelsohly mhc2scaleenhancesidentificationofimmunogenicneoantigens